PMC9109900_01
Timeline for Case 1. (A) Axial cerebral magnetic resonance imaging (MRI) in T2-weighted sequences before lenalidomide treatment: the red arrow shows left frontal lobe hyperintensity. (B) Axial cerebral MRI: the red arrow shows the left frontal lobe lesion signal disappeared after lenalidomide treatment.
JIR-15-2891-g0001.jpg
PMC9109900_01_JIR-15-2891-g0001.jpg
f0001
However, multiple intracranial lesions with meningeal enhancement were observed in brain magnetic resonance imaging (MRI) (Figure 1A). T2-weighted MRI revealed a significant reduction in the signal in the left frontal lobe lesion (Figure 1B).
PMC9109900_02
Timeline for Case 2. (A) Axial cerebral magnetic resonance imaging (MRI) in T2-weighted sequences before lenalidomide treatment: the red arrow shows multiple regions of thickening and enhancement in the meninges. (B) Axial cerebral MRI: the red arrow shows the degree of meningeal enhancement was significantly reduced after lenalidomide treatment.
JIR-15-2891-g0002.jpg
PMC9109900_02_JIR-15-2891-g0002.jpg
f0002
Brain MRI revealed multiple regions of thickening and meningeal enhancement (Figure 2A). Brain MRI revealed a significantly reduced degree of meningeal enhancement (Figure 2B).